Competition Bureau obtains court order in investigation into Keyera’s deal to buy U.S. firm Plains

The Competition Bureau obtained a Federal Court order to gather information on Keyera Corp.'s proposed $5.15 billion acquisition of Plains' Canadian natural gas liquids business, citing potential for a substantial lessening of competition. The bureau is assessing barriers to competitors and whether the deal would entrench Keyera in the energy infrastructure market; Inter Pipeline Ltd. has been ordered to produce relevant records. The assets include 193,000 bpd of fractionation capacity, 23 million barrels of storage and over 2,400 km of pipeline; Keyera now expects to close in May rather than the end of Q1 as regulatory review continues.

Analysis

Regulatory scrutiny materially increases deal execution risk for the acquirer and creates a binary outcome set: approval with remedies (modest value leakage), or structural remedies/block (large immediate value haircut for the buyer). The mechanical impact is straightforward — any forced divestiture or new third‑party access rules will dilute expected synergies tied to fractionation and storage scale and compress transaction multiple by an incremental ~15–30% versus a clean close.

Second‑order winners include owners of unencumbered fractionation and storage capacity (peers able to offer tolling or incremental takeaway) because regulators commonly steer flows toward preserving competition rather than boosting a single owner; these peers can monetize captive shippers or short‑term storage premiums if access mandates are imposed. Conversely, financiers and equity holders in the acquirer face funding/timing risk: extended closing windows increase cost of capital and tighten near‑term free cash flow, which is asymmetric negative for the buyer relative to smaller regional competitors.

Timing is event‑driven: expect near‑term headline volatility around bureau filings and a 3–12 month review window for remedies or litigation. Reversal catalysts include a negotiated remedy (reduces downside to ~10–15%) or an adverse finding that forces asset carve‑outs (downside 20–40% to the buyer persisted until assets reprice). Watch for spokespeople, statement of objections, or interim undertakings as high‑information triggers.

From a capital allocation perspective, prefer option‑structured downside protection and small, dollar‑neutral pair trades over outright directional exposure — the market is likely to overshoot on headline risk but underprice conditional remedy outcomes that preserve most long‑term value.

Key Decisions for Investors

• Tactical short KEY.TO equity (size 2–3% sector book) with 3–9 month horizon — target 20–30% downside if remedies or divestiture required; set protective buy‑stop at 10–12% adverse move to cap technical squeeze risk.
• Pair trade: short KEY.TO / long ENB.TO or TRP.TO, dollar‑neutral, 6–12 month horizon — benefits if regulators redistribute access or volumes; target 10–18% relative outperformance of the long leg, stop if spread compresses by more than 8% favoring short leg.
• Buy 9–12 month KEY.TO puts ~15–20% OTM sized to 0.5–1% NAV to asymmetrically capture downside; consider financing by selling nearer‑dated 6–9 month calls (covered or ratio) to lower cost basis — expect theta to work for short calls if review prolongs.
• If long exposure to KEY.TO exists, hedge by selling short‑dated (60–120 day) out‑of‑the‑money calls and buying long‑dated puts to create a collar; this preserves upside from eventual approval while limiting 6–12 month downside to <20%.